BRPI0607838A2 - preparação de uma quinoxalina substituìda de pureza elevada - Google Patents

preparação de uma quinoxalina substituìda de pureza elevada

Info

Publication number
BRPI0607838A2
BRPI0607838A2 BRPI0607838-9A BRPI0607838A BRPI0607838A2 BR PI0607838 A2 BRPI0607838 A2 BR PI0607838A2 BR PI0607838 A BRPI0607838 A BR PI0607838A BR PI0607838 A2 BRPI0607838 A2 BR PI0607838A2
Authority
BR
Brazil
Prior art keywords
preparation
quinoxaline
high purity
substituted high
substituted
Prior art date
Application number
BRPI0607838-9A
Other languages
English (en)
Inventor
Frank Robert Busch
Joel Michael Hawkins
Lanson Georgios Mustakis
Terry Gene Sinay Jr
Timothy James Norman Watson
Gregory John Withbroe
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0607838A2 publication Critical patent/BRPI0607838A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

PREPARAçãO DE UMA QUINOXALINA SUBSTITUìDA DE PUREZA ELEVADA. A presente invenção compreende um processo melhorado para a preparação de quinoxalina substituida I por ciclização da dianilina correspondente.
BRPI0607838-9A 2005-02-24 2006-02-21 preparação de uma quinoxalina substituìda de pureza elevada BRPI0607838A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65629605P 2005-02-24 2005-02-24
PCT/IB2006/000351 WO2006090236A1 (en) 2005-02-24 2006-02-21 Preparation of high purity substituted quinoxaline

Publications (1)

Publication Number Publication Date
BRPI0607838A2 true BRPI0607838A2 (pt) 2009-06-13

Family

ID=36405938

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607838-9A BRPI0607838A2 (pt) 2005-02-24 2006-02-21 preparação de uma quinoxalina substituìda de pureza elevada

Country Status (15)

Country Link
US (1) US20080275051A1 (pt)
EP (1) EP1866308B1 (pt)
JP (1) JP2008531540A (pt)
KR (1) KR20070098942A (pt)
CN (1) CN101128462A (pt)
AT (1) ATE411994T1 (pt)
AU (1) AU2006217616A1 (pt)
BR (1) BRPI0607838A2 (pt)
CA (1) CA2598533A1 (pt)
DE (1) DE602006003320D1 (pt)
ES (1) ES2313625T3 (pt)
IL (1) IL185013A0 (pt)
MX (1) MX2007010375A (pt)
RU (1) RU2007131535A (pt)
WO (1) WO2006090236A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2086977A2 (en) 2006-11-09 2009-08-12 Pfizer Products Inc. Polymorphs of nicotinic intermediates
WO2009065872A2 (en) * 2007-11-20 2009-05-28 Medichem, S.A. Improved processes for the synthesis of varenicline l-tartrate
US8039620B2 (en) 2008-05-22 2011-10-18 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline L-tartrate
US20090318695A1 (en) * 2008-06-19 2009-12-24 Vinod Kumar Kansal Processes for the preparation of varenicline and intermediates thereof
WO2010005643A1 (en) * 2008-07-10 2010-01-14 Teva Pharmaceutical Industries Ltd. Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
EP2438054A1 (en) 2009-06-22 2012-04-11 Teva Pharmaceutical Industries Ltd. Solid states forms of varenicline salts and processes for preparation thereof
US20120277433A1 (en) * 2009-12-29 2012-11-01 Mahendranath Rao Narasimha Rao Process for the preparation of substituted quinoxalines
EP2545054A1 (en) * 2010-03-09 2013-01-16 Actavis Group Ptc Ehf Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity
US20120004239A1 (en) * 2010-06-11 2012-01-05 Medichem, S.A. Process for Preparing Quinoxaline Derivatives
CN113956255A (zh) * 2020-07-20 2022-01-21 威智医药有限公司 一种伐尼克兰中间体、伐尼克兰及其盐的制备方法
WO2022035434A1 (en) 2020-08-14 2022-02-17 Almatica Pharma Llc Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof
WO2022222019A1 (en) * 2021-04-20 2022-10-27 Suzhou Fude Zhaofeng Biochemical Technology Co., Ltd Total synthesis of varenicline
CN115894488A (zh) * 2021-08-20 2023-04-04 威智医药有限公司 低亚硝胺杂质含量的酒石酸伐尼克兰原料药及其制备方法
CN114349701B (zh) * 2022-01-07 2024-04-05 江苏豪森药业集团有限公司 一种酒石酸伐尼克兰中间体的制备方法
EP4241775A1 (en) 2022-03-11 2023-09-13 Par Pharmaceutical, Inc. Tablet comprising varenicline and process of preparation thereof
US11602537B2 (en) 2022-03-11 2023-03-14 Par Pharmaceutical, Inc. Varenicline compound and process of manufacture thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50069B (sr) * 1997-12-31 2009-01-22 Pfizer Products Inc., Aril kondenzovana azapoliciklična jedinjenja
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
GEP20053712B (en) * 2001-05-14 2005-12-26 Pfizer Prod Inc Tartrate Salts of 5,8,14-Triazatetracyclo {10.3.1.0²,11.04,9}-Hexadeca-2(11),3,5,7,9-Pentaene and Pharmaceutical Compositions Thereof
WO2004108725A1 (en) * 2003-06-04 2004-12-16 Pfizer Products Inc. Preparation of substituted quinoxalines from the dianline with 2,3-dihydroxy-1,4-dioxane

Also Published As

Publication number Publication date
JP2008531540A (ja) 2008-08-14
AU2006217616A1 (en) 2006-08-31
CN101128462A (zh) 2008-02-20
IL185013A0 (en) 2007-12-03
EP1866308B1 (en) 2008-10-22
KR20070098942A (ko) 2007-10-05
EP1866308A1 (en) 2007-12-19
ES2313625T3 (es) 2009-03-01
ATE411994T1 (de) 2008-11-15
WO2006090236A1 (en) 2006-08-31
RU2007131535A (ru) 2009-03-27
CA2598533A1 (en) 2006-08-31
US20080275051A1 (en) 2008-11-06
DE602006003320D1 (de) 2008-12-04
MX2007010375A (es) 2007-09-25

Similar Documents

Publication Publication Date Title
IL185013A0 (en) Preparation of high purity substituted quinoxaline
MX339476B (es) Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
MX342683B (es) Analogos de ciclopamina.
NO20076371L (no) Fremgangsmate for fremstilling av fenoliske 4-bifenylylazetidin-2-oner
ES2338590T3 (es) Procedimiento regioselectivo de preparacion de benzoimidazoltiofenos.
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
CY1112467T1 (el) Παραγωγα 1-θειο-d-γλυκιτολης
MXPA05012680A (es) Indoles novedosos de 3-azufre sustituidos.
MX2007006179A (es) Tetrahidrocarbazoles como agentes activos para inhibir la produccion del factor de crecimiento endotelial vascular por control de la traduccion.
UA90706C2 (ru) Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
NI200900151A (es) Nuevo procedimiento de síntesis de la agomelatina.
EA201070804A1 (ru) (аза)индольное производное, замещенное по положению 5, содержащая его фармацевтическая композиция, промежуточные соединения и способ их получения
NI200900153A (es) Nuevo procedimiento de síntesis de la agomelatina.
TN2010000045A1 (en) Novel herbicides
NO20074047L (no) Ny fremgangsmate for fremstilling av substituerte indoler
NO20081617L (no) Metoder for fremstilling av Glutaminsyrederivater
MX2007011847A (es) Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
TN2009000536A1 (en) Novel herbicides
TW200728258A (en) Novel compounds
NI200900152A (es) Nuevo procedimiento de síntesis de la agomelatina
EA200801365A1 (ru) Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
TW200728310A (en) Process for the preparation of ferri-succinylcasein
EA200801549A1 (ru) Новые производные фенантридина в качестве антагонистов брадикинина
DK1926732T3 (da) Fremgangsmåde til fremstillingen af carbapenemforbindelser

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.